Q-omics provides the consensus-scored BTC profile across patient tissues and cancer cell-line models. BTC expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BTC is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, BTC RNA expression shows 17,220 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where BTC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTC survival associations across molecular data types. BTC RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTC RNA expression–survival associations across cancer types. High BTC expression shows unfavorable associations in HNSC and UVM, but favorable associations in KIRC, MESO, COAD and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BTC RNA expression.
This table summarizes BTC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BTC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTC shows lower tumor expression in KIRC, HNSC, LUSC, BLCA, UCEC and COAD. The KIRC box plot shows higher BTC RNA expression in normal versus tumor tissue (log2 FC = −1.681, t-test p < 0.001).
This table shows molecular features associated with BTC in patient tissues and cancer cell lines. In patient samples, BTC shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, BTC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OVARY.
